Scalper1 News
The chairman and a senior member of the U.S. Senate Finance Committee on Friday issued a battery of questions to Gilead Sciences (GILD) about how it priced its blockbuster hepatitis C drug Sovaldi, adding to the chorus of objections to the product’s $1,000-per-pill price. The market was unfazed, however, with Gilead stock up a fraction in morning trading on the stock market today. Sens. Ron Wyden, D.-Ore., and Charles Grassley, R.-Iowa, published Scalper1 News
Scalper1 News